Skip to content
OpenCapital
Get started

Rapport Therapeutics, Inc. RAPP Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
1.9×-0.4×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
27.8×+10.1×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
15.9×+7.4×
Biohaven logo
BiohavenBHVN
7.4×+5.1×
Septerna, Inc. logo
Septerna, Inc.SEPN
4.7×-27.5×

Other financials

Income statement

See full
Revenue$20.0M—
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%—
Debt / equity0×0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

quick assets/total current liabilities=27.1×

Based on the most recent quarter.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s quick ratio?
Rapport Therapeutics, Inc. (RAPP) reported quick ratio of 27.1× in Q1 2026.
How has Rapport Therapeutics, Inc.'s quick ratio changed year-over-year?
Rapport Therapeutics, Inc.'s quick ratio decreased by 12.7% year-over-year, from 31× to 27.1×.
What is the long-term trend for Rapport Therapeutics, Inc.'s quick ratio?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s quick ratio has grown at a 23.6% compound annual growth rate (CAGR), from 17.1× to 26.2×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.